An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. (2022)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/cpt.2463
PubMed Identifier: 34699618
Publication URI: http://europepmc.org/abstract/MED/34699618
Type: Journal Article/Review
Volume: 111
Parent Publication: Clinical pharmacology and therapeutics
Issue: 3
ISSN: 0009-9236